ARTICLE | Finance
Plus: Structure, Annexon and Summit follow clinical readouts by raising money
By Paul Bonanos, Director of Biopharma Intelligence
June 7, 2024 9:06 PM UTC
Ending a two-month drought for biotech IPOs on NASDAQ, Rapport enjoyed a double-digit first-day pop on Friday after pricing its $136 million public offering squarely within expectations.
Rapport Therapeutics Inc. (NASDAQ:RAPP) sold 8 million shares, as expected, at the $17 midpoint of its proposed range. Accompanying the offering was an $18 million private placement of nearly 1.1 million shares at the same price, giving Rapport gross proceeds of $154 million…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652636/public-equity-report-rapport-posts-healthy-first-day-gain-as-telix-grail-head-for-nasdaq